Literature DB >> 29133578

Orlistat-induced oxalate nephropathy: an under-recognised cause of chronic kidney disease.

Laurence Richard Solomon1, Andrew Christopher Nixon1, Leanne Ogden1, Beena Nair2.   

Abstract

Two patients developed kidney failure due to oxalate deposition in the kidney while taking orlistat. Cessation of orlistat was followed by partial recovery of kidney function. The mechanism by which orlistat causes hyperoxaluria and the management of orlistat-induced oxalate nephropathy is reviewed. We suggest that all patients taking orlistat are at risk of this condition, which may develop insidiously and is easily overlooked. Monitoring of kidney function of patients taking orlistat is warranted. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  Acute Renal Failure; Contraindications And Precautions; Metabolic Disorders; Obesity (nutrition); Renal System

Mesh：

Substances：

Year:  2017        PMID： 29133578      PMCID： PMC5695294          DOI： 10.1136/bcr-2016-218623

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  30 in total

1.  Rapidly progressive renal failure associated with successful pharmacotherapy for obesity.

Authors:  Aisling E Courtney; Declan M O'Rourke; Alexander Peter Maxwell
Journal:  Nephrol Dial Transplant       Date:  2006-11-22       Impact factor: 5.992

2.  Orlistat, an under-recognised cause of progressive renal impairment.

Authors:  Andrew K Coutinho; Gerald R Glancey
Journal:  Nephrol Dial Transplant       Date:  2013-09-18       Impact factor: 5.992

Review 3.  AJKD Atlas of Renal Pathology: Oxalosis.

Authors:  Agnes B Fogo; Mark A Lusco; Behzad Najafian; Charles E Alpers
Journal:  Am J Kidney Dis       Date:  2017-03       Impact factor: 8.860

4.  Acute oxalate nephropathy secondary to orlistat-induced enteric hyperoxaluria.

Authors:  Tony K Kwan; Steve J Chadban; Paul R McKenzie; John R Saunders
Journal:  Nephrology (Carlton)       Date:  2013-03       Impact factor: 2.506

5.  Orlistat-induced oxalate nephropathy may be dose-independent and present as a late manifestation.

Authors:  Neville R Dossabhoy; Scott McRight; Bhupinder Sangha; Sarah Khan; Cherinet Adgeh
Journal:  J La State Med Soc       Date:  2013 Sep-Oct

Review 6.  Orlistat, a new lipase inhibitor for the management of obesity.

Authors:  A M Heck; J A Yanovski; K A Calis
Journal:  Pharmacotherapy       Date:  2000-03       Impact factor: 4.705

Review 7.  Enteric hyperoxaluria: an important cause of end-stage kidney disease.

Authors:  Lama Nazzal; Sonika Puri; David S Goldfarb
Journal:  Nephrol Dial Transplant       Date:  2015-02-20       Impact factor: 5.992

8.  Fat malabsorption induced by gastrointestinal lipase inhibitor leads to an increase in urinary oxalate excretion.

Authors:  Renato Ribeiro Nogueira Ferraz; Hans-Göran Tiselius; Ita Pfeferman Heilberg; Ita Pfeferman Heiberg
Journal:  Kidney Int       Date:  2004-08       Impact factor: 10.612

9.  Reactive oxygen species, inflammation and calcium oxalate nephrolithiasis.

Authors:  Saeed R Khan
Journal:  Transl Androl Urol       Date:  2014-09-01

10.  Acute oxalate nephropathy associated with orlistat: a case report with a review of the literature.

Authors:  Dhara Chaudhari; Conchitina Crisostomo; Charles Ganote; George Youngberg
Journal:  Case Rep Nephrol       Date:  2013-05-08
View more
  7 in total

1.  Case - Orlistat-induced calcium oxalate crystalluria.

Authors:  Greta Handing; Ujval Ishu Pathak; Adithya Balasubramanian; Alexander Liu; Wesley A Mayer
Journal:  Can Urol Assoc J       Date:  2022-10       Impact factor: 2.052

2.  The association of calcium oxalate deposition in kidney allografts with graft and patient survival.

Authors:  Ragnar Palsson; Anil K Chandraker; Gary C Curhan; Helmut G Rennke; Gearoid M McMahon; Sushrut S Waikar
Journal:  Nephrol Dial Transplant       Date:  2020-05-01       Impact factor: 5.992

Review 3.  Management of Obesity in Adults with CKD.

Authors:  Allon N Friedman; Lee M Kaplan; Carel W le Roux; Philip R Schauer
Journal:  J Am Soc Nephrol       Date:  2021-02-18       Impact factor: 10.121

Review 4.  Calcium oxalate crystal deposition in the kidney: identification, causes and consequences.

Authors:  R Geraghty; K Wood; J A Sayer
Journal:  Urolithiasis       Date:  2020-07-27       Impact factor: 3.436

5.  Secondary Oxalate Nephropathy: A Systematic Review.

Authors:  Nuttha Lumlertgul; Monchai Siribamrungwong; Bertrand L Jaber; Paweena Susantitaphong
Journal:  Kidney Int Rep       Date:  2018-07-29

Review 6.  Metabolic Surgery to Treat Obesity in Diabetic Kidney Disease, Chronic Kidney Disease, and End-Stage Kidney Disease; What Are the Unanswered Questions?

Authors:  William P Martin; James White; Francisco J López-Hernández; Neil G Docherty; Carel W le Roux
Journal:  Front Endocrinol (Lausanne)       Date:  2020-08-17       Impact factor: 5.555

Review 7.  Medical therapy for nephrolithiasis: State of the art.

Authors:  Igor Sorokin; Margaret S Pearle
Journal:  Asian J Urol       Date:  2018-09-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.